Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma Journal Article


Authors: Ferrone, C. R.; Finkelstein, D. M.; Thayer, S. P.; Muzikansky, A.; Fernandez-del Castillo, C.; Warshaw, A. L.
Article Title: Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
Abstract: Purpose Different prognostic factors stratify patients with pancreatic adenocarcinoma. The purpose of this study was to determine whether preoperative CA19-9 levels can predict stage of disease or survival and whether a change in preoperative to postoperative CA19-9 or the postoperative CA19-9 predicts overall survival. Patients and Methods Four hundred twenty-four consecutive patients with pancreatic adenocarcinoma underwent resection between January 1, 1985 and January 1, 2004. Of the patients with a bilirubin less than 2 mg/dL, 176 had preoperative CA19-9 values, and 111 had pre- and postoperative CA19-9 values. Survival was measured from the first postoperative CA19-9 level measured (median, 39 days) until death or last follow-up. A multivariate failure time model was fit using clinical, operative, pathologic, and adjuvant treatment characteristics, and a categorization was defined by the values and changes in CA19-9 before and after surgery. Results Of the 176 patients, 128 (73%) had T3 lesions, and 99 (56 /0) had N1 disease; 138 patients (78%) underwent pancreaticoduodenectomy. Median preoperative CA19-9 levels were lower in NO patients compared with patients with positive nodes (nine v 164 U/mL, respectively; nonparametric P = .06) and in T1/T2 patients versus T3 patients (41 v162 U/mL, respectively; P = .03). Median follow-up time (n = 111) was 1.8 years (range, 1 to 12.9 years), with overall actuarial 1-, 3-, and 5-year survival rates of 70%, 36%, and 30%, respectively. Significant predictors of survival on multivariate analysis included a decrease in CA19-9 (P = .0005), negative lymph nodes (P = .001), lower T stage (P = .0008), and postoperative CA19-9 less than 200 U/mL (P = .0007). Conclusion In patients with pancreatic adenocarcinoma, preoperative CA19-9 correlates with stage of disease. Both a postoperative decrease in CA19-9 and a postoperative CA19-9 value of less than 200 U/mL are strong independent predictors of survival, even after adjusting for stage. CA19-9 levels should be included in a patient's perioperative care and should be considered for prognostic nomograms.
Keywords: antigen; carcinoma; serum; tumor-markers; ca-19-9
Journal Title: Journal of Clinical Oncology
Volume: 24
Issue: 18
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2006-06-20
Start Page: 2897
End Page: 2902
Language: English
ACCESSION: WOS:000238556600034
DOI: 10.1200/jco.2005.05.3934
PROVIDER: wos
PMCID: PMC3817569
PUBMED: 16782929
Notes: --- - Article - "Source: Wos"
Altmetric
Citation Impact
MSK Authors
  1. Cristina Ferrone
    32 Ferrone